Trade Filings
Managers Stocks Filings Superinvestors
Signals Institutional Buying Institutional Selling Insider Activity 13D & 13G Watch Sector Rotation
Tools Stock Screener Manager Screener Compare Managers Consensus Baskets All Research Tools Data API
Learn & AI Learn Ask the Data AI Agents
News ★ Saved
About About us Methodology Contact Disclaimer
Reader
DATA PLANS

Historical data downloads — coming with accounts.

API GATEWAY

Free read-only JSON access to the site's cached data.

Dark mode

🧭 Guided View
New to markets — prices, yields, YTD, market cap? We explain every term as you browse, in plain English. Same data, with the help built in.

⚡ Expert View
You already know the market. Just the data — clean, fast and compact, with no extra explanations. This is the default view.

Interface language
Security record · archived quarter

SMMT

Summit Therapeutics Inc. · Healthcare · Biotechnology

14.29 +7.0% mkt cap $11.40B quote delayed (FMP) · as of Aug 26 16:08 UTC — separate from filing data below

Q2 2026 Q1 2026 Q4 2025 Q3 2025 Q2 2025 Q1 2025 Q4 2024 Q3 2024
8Tracked holders
0Δ holders
10.94MShares held
$239.67MReported value
+1New positions
−1Exits
Strongly Rising Conviction score 54/100 How these are computed → Explain this at the Research Desk →

Momentum inputs (comparable managers): holder breadth 0.0% · share flow +30.0% · net new positions 0.0%formula

All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q3 2024

Ownership over time
QuarterHoldersΔSharesReported valueNewExits
Q2 2026 86 +5 84.29M $1.23B +8 −2
Q1 2026 82 +1 68.40M $1.29B +10 −10
Q4 2025 81 0 72.69M $1.27B +1
Q3 2025 15 -1 45.07M $931.26M +1 −3
Q2 2025 14 0 38.14M $811.62M +1 −1
Q1 2025 11 +1 18.29M $352.78M +1
Q4 2024 10 +1 17.85M $318.58M +1
Q3 2024 8 0 10.94M $239.67M +1 −1
Q2 2024 8 7.47M $58.27M
Holder count
Who holds it · Q3 2024
#ManagerSharesΔ sharesValueTheir weightHeld
1 T. Rowe Price 5.44M +166.4% $119.13M 0.0% ▲ Add 2 SEC ↗
2 T. Rowe Price 5.44M +166.4% $119.13M 0.0% ▲ Add 2 SEC ↗
3 Geode Capital Management (passive) 3.10M +4.6% $67.90M 0.0% ▲ Add 2 SEC ↗
4 Geode Capital Management (passive) 3.10M +4.6% $67.90M 0.0% ▲ Add 2 SEC ↗
5 Millennium Management 1.22M -37.1% $26.77M 0.0% ▼ Trim 2 SEC ↗
6 Citadel Advisors 650.83K New $14.25M 0.0% New 1 SEC ↗
7 D. E. Shaw & Co. 402.17K +1254.1% $8.81M 0.0% ▲ Add 2 SEC ↗
8 AQR Capital Management 68.52K +10.3% $1.50M 0.0% ▲ Add 2 SEC ↗
9 AQR Capital Management 68.52K +10.3% $1.50M 0.0% ▲ Add 2 SEC ↗
10 Wellington Management 44.19K -83.5% $967,718 0.0% ▼ Trim 2 SEC ↗
11 Wellington Management 44.19K -83.5% $967,718 0.0% ▼ Trim 2 SEC ↗
12 Wellington Management 44.19K -83.5% $967,718 0.0% ▼ Trim 2 SEC ↗
13 Wellington Management 44.19K -83.5% $967,718 0.0% ▼ Trim 2 SEC ↗
14 Gotham Asset Management 15.91K -18.4% $348,385 0.0% ▼ Trim 2 SEC ↗

“Their weight” = the position's share of that manager's reported 13F equity value — the conviction measure. ✦ = curated manager.

New buyers

Citadel Advisors $14.25M 0.0%

Exited

Arrowstreet Capital $1.10M was 0.0%

Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 223 holders, 118.88M shares, $2.10B reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.

Frequently co-owned

What else this security's tracked holders most often hold — shared-ownership counts, not fundamental relationships.

Provenance: Ownership from parsed 13F common-stock positions (tracked universe, comparable sets for changes); insider rows from Forms 3/4/5; stakes from Schedules 13D/13G; every filing links to its original on SEC EDGAR. Reporting period: Q3 2024 · Methodology · Get this via the API